Searched for
ANTI EPILEPSY
These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Volatility as opportunity, depends on framework of mind: 5 mid-caps from different sectors with upside potential of up to 31%The Indian stock market is no longer correcting only because of sentiment. It is now adjusting to the possibility of weaker numbers in the ...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Child could not focus on studies, showed tantrums while eating. CMC Vellore doctor cracks the case of rare eating epilepsyA 12-year-old boy from Andhra Pradesh was misdiagnosed for months until a neurologist identified his strange mealtime behavior as Eating Ep...
- A boy kept fainting during baths. Hyderabad doctor reveals this rare disease is found in many parts of south IndiaSai Teja, a twelve-year-old from Andhra Pradesh, suffered mysterious spells after hot water baths. Doctors initially dismissed his conditio...
- Akumentis Healthcare launches drug for treatment of epilepsy"We understand the immense physical and emotional toll that frequent seizures can have on patients and their families," Akumentis Executive...
- 'Anglo-French drugs to focus on specialty segments'AFDIL president Nirbhay Kanoria told ET in an interview that the 100-year-old pharma company is focusing on specialty therapeutic segments ...
- Silent, subtle & unseen: Why are seizures hard to diagnose? Identifying and improving gaps in epilepsy careA seizure is caused by sudden uncontrolled electrical activity from a group of neurons.
- Lupin gets USFDA nod to market generic drugThe company has received approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA), Vigabatri...
- Sun Pharma to launch complete range of generic anti-epilepsy drugThe drug major introduced Brevipil (Brivaracetam) tablet in strengths of 25 mg/50 mg/75 mg/100 mg on February 21, while Brevipil oral solut...
- Planned pregnancy can help 90% epileptic women have healthy babiesNew Delhi, Nov 19 (IANS) Planned pregnancy can help 90 per cent of epileptic women deliver healthy babies, said doctors.
- Delhi High Court comes to Intas rescue, stops Arinna Lifescience for trademark violationDelhi High Court gave relief to Ahmedabad-based drug maker, Intas Pharmaceuticals, by granting an ex-parte injunction against the sale of V...
- Dr Reddy's launches anti-epilepsy tablets in US marketDr Reddy's Laboratories said it has launched its generic Lamotrigine extended-release tablets, used for treating epilepsy, in the American ...
- Wockhardt gets USFDA nod to market anti-epilepsy tabletsThe tablets will be manufactured at the company's facility at Aurangabad.
- Lupin gets USFDA nod to market generic anti-epilepsy drugDrug maker Lupin today said it has received final approval from the US health regulator to market a generic version of UCB's Keppra Oral So...
- Lupin gets final US FDA nod for generic anti-epileptic drugLupin is the 5th largest generics player in the US (by prescriptions), the only Asian company to achieve that distinction.
- US drug agency warns of suicide risk with epilepsy drugsEpilepsy drugs used by millions may increase the risk of suicidal thoughts or behavior, US regulators have warned.
- Dr Reddy's, UCB settle patent rowThis out of court settlement will enable Dr Reddy’s to launch its generic version of Keppra soon. The market size of Keppra is around one b...
Load More
